development of multiple sclerosis in this study.
There is general agreement that a proportion of pa-multiple sclerosis after optic neuritis is 50% or tients presenting with unilateral optic neuritis even-more,2 -5 whereas the frequency reported in tually develop multiple sclerosis;' what remains American studies is lower6-10 possibly reflecting geouncertain is the percentage of individuals that follow graphical or ethnic differences in susceptibility' II this course and when the conversion is likely to occur. and the application of varying diagnostic criteria. 12 13 Most European studies report that the incidence of Multiple sclerosis is most likely to develop within the first 5 years5 -7 10 after optic neuritis, but the proportion of patients who develop disseminated lesions continues to rise with length of follow-up. ' 14 Using an Multiple sclerosis following optic neuritis which may influence outcome in patients with optic neuritis. They include age of onset and sex,9 presence of oligoclonal immunoglobulins in cerebrospinal fluid'6 and recurrence.9 15 17 The risk of multiple sclerosis is lower after simultaneous than sequential bilateral optic neuritis in adults, but higher in both instances than following bilateral optic neuritis in childhood. 2 17 The association between the HLA system and multiple sclerosis prompted immunogenetic studies in patients with optic neuritis. Arnason et al '8 found no significant associations with antigens of the HLA-A and -B series, whereas Platz et al '9 reported that the frequencies of HLA-A3, B7 (fig 1) indicating the number of patients seen in the initial review (1976-77), how they were then classified, and the results of review during 1983-85. Eighty eight out of the 146 patients were originally classified as having optic neuritis only (ON-only) ofwhom we were able to reassess 67 (76%) after an interval of 5-8-30-5 years (median 10-1 years, mean 11-3 years) from the original episode. Twenty four of the 67 patients (36%) had experienced neurological symptoms or developed neurological signs outside the optic nerves since our previous Fifty eight out of 146 patients were originally classified as having developed multiple sclerosis; 34/58 (59%) were reviewed and the diagnosis confirmed. Nine, of 10 patients, classified as clinically probable multiple sclerosis in the original series had developed further neurological features and could now be classified as having clinically definite multiple sclerosis. The remaining patient had had no further neurological episodes since the last review.
The 45 patients lost to follow-up consisted of 21/88 (24%) patients from the original ON-only group and 24/58 (41%) patients with ON/MS. This bias in patient recall (p < 0.05) should be considered when interpreting our present results.
Overall, 58/101 (57%) patients had developed multiple sclerosis by 1983-85 after a mean follow-up period of 11-6 years (range 5-9-30-6 years), and 51 (88%) of these patients had clinically definite disease. This compared with 58/146 (40%) patients, of whom 62% had clinically definite disease, after 3*9 years (range 0 9-23 years), in the first survey. 24/45 (53%) patients not reviewed in 1983-85 were already known to have developed multiple sclerosis at the time of the first survey. The minimum observed proportion of patients developing multiple sclerosis after nearly 12 years of follow-up (57%) is similar to the figure pre- 
Discussion
In 1978 we observed that 40% of 146 patients with optic neuritis had developed multiple sclerosis after a mean interval of 3 9 years and identified three risk factors for this event. Since our original survey a further third of the patients whom we have been able to review have developed multiple sclerosis and the overall minimum observed frequency of multiple sclerosis is now 57% after 11 6 years follow-up; this is similar to the figure previously predicted (60%) at 8 years using actuarial methods. Applying this type of analysis to the present group it is predicted that a further 18% of patients with optic neuritis (75% overall) will develop multiple sclerosis after 15 years follow-up. This figure approximates closely to that predicted by
Hutchinson"2 for Northern Ireland, using a similar analysis (78% at 15 years). But our figures for observed and predicted conversion to multiple sclerosis are falsely low because a significantly higher proportion of 45 patients lost to follow-up were from the group who had already developed multiple sclerosis at the time of the first survey. If these patients are taken into consideration the observed and predicted frequencies of conversion to multiple sclerosis are both higher and approach the observed figure of 85% in McAlpine's2 reassessment of Lynn's32 data. We found significantly raised frequencies of HLA-DR2 in patients with isolated optic neuritis (p < 0-01; RR = 2-9) and in those who subsequently developed multiple sclerosis (p < 0 005; RR = 4.9) compared with the normal population. The higher frequencies and relative risks in the patients who developed multiple sclerosis suggest that HLA-DR2 may be a significant risk factor for the development of dissemination of lesions, but the difference was not significant. While DR2 was associated with an increased susceptibility to both optic neuritis and multiple sclerosis, on the present evidence, it did not appear to influence long term progression from the former to the latter.
HLA-DR3 was increased in the group of patients with ON/MS but not in patients with ON-only. This association could not be examined in 1978. Based on actuarial analysis over 95% of DR3 + ve patients will have developed multiple sclerosis within 15 years compared with 63% of those without this antigen. Patients who possessed both DR2 and DR3 were even more likely to develop multiple sclerosis. This finding supports the suggestion of Madigand et al"3 that independent genes linked to DR2 and DR3 complement each other in determining susceptibility to multiple sclerosis. If confirmed in a larger study, the question would arise whether this subgroup of patients, with such a high relative risk for developing multiple sclerosis after optic neuritis, might, when an Multiple sclerosis following optic neuritis effective form of treatment is developed, benefit from its institution during the presenting episode.
It is of interest that HLA-DQwl shows a significantly increased frequency in patients with ON/MS. We found an even higher association between this antigen and all forms of multiple sclerosis in the Grampian region of North East Scotland. 34 The frequency of HLA-DR2 in patients with multiple sclerosis in the Grampian region was high (49%), but similar to that found in a local control population (41%).
In 1978, progression of isolated optic neuritis to multiple sclerosis appeared to correlate with the presence of the B lymphocyte alloantigen, BT 101. At the 1978 International Histocompatibility Workshop the sera defining BT 101 were found to correlate significantly with DR2, but further reactions were also found with cells from HLA-DR1 and DRw6 positive individuals. HLA-DR1, -2, and -w6 are now known to be in linkage disequilibrium with the recently defined antigen DQwl,2" and the sera used to define BT 101 ("BEW" and "SEW") have been found to correlate more closely with this antigen than with DR2 (unpublished data). This is consistent with our findings which suggest that the sera defining BT 101 are of broad specificity reacting with both DR2 and DQwl positive cells but correlating more closely with DQwl.
BT 101 was associated with an increased risk of developing multiple sclerosis in the earlier study but this finding is not confirmed in the present study in which the follow-up has been extended. There are several possible reasons for these conflicting results. First, since 1978, there have been advances in understanding the structure of the HLA system; new methods and reagents are now available for defining Class II antigens. Seven patients classified as BT 101 positive in 1978 are negative for both HLA-DQwl and HLA-DR2. Conversely, six patients classified as BT 101 negative in 1978 are positive for HLA-DQwl, and/or HLA-DR2, using modern typing reagents. Studies carried out at different times and using different reagents cannot be easily compared. A second important factor is the length of follow-up which has been extended from a mean of 4 years, in the original study, to 11 -6 years in the present study. The separation of the actuarial curves plotted for cases with and without BT 101 during the initial follow-up have not been maintained beyond 10 years so that overall the difference is no longer observed; given the high rates of conversion to multiple sclerosis after 10 years the later parts of the curve are necessarily based on fewer observations, especially in patients with ONonly, and are therefore subject to the effect of sampling errors; in our recent review 40% of the original ON/MS group but only 23% of the ON-only cases 763 could not be reassessed.
The incidence of "observed" cases of multiple sclerosis developing after optic neuritis in the former study (40%), was less than that observed in other studies from the United Kingdom with a longer period of follow-up.45 For example, McAlpine2 reanalysed Lynn's32 original data (which showed a 50% overall incidence of multiple sclerosis), by excluding all cases of optic neuritis followed-up for less than 5 years, and found that a much higher percentage of patients (85%) had developed multiple sclerosis. In our study, since 75% of patients with optic neuritis may subsequently develop multiple sclerosis, even if all BT 101 positive cases convert, some BT 101 negative individuals must also develop multiple sclerosis as has in fact been observed.
What then is the significance of the documented association with DR2? It is clear from our study that DR2 is associated with demyelinating lesions whether they are confined to the optic nerve or are more widespread in the CNS but on the present evidence its presence does not appear to influence long term conversion of the isolated to disseminated form of disease. Additional factors might be important and we have produced evidence implicating HLA-DR3, whether it is present in isolation or in combination with HLA-DR2. Factor B alleles, previously thought to influence progression to multiple sclerosis,21 appear not to be important in this respect. Our present results are supported by findings in a larger group of patients, from the Grampian region of Scotland, in which no significant deviation of the distribution of Bf alleles was found between groups of patients with markedly contrasting clinical courses.
Thirty six per cent of all patients reviewed iii the present series had recurrent optic neuritis, and of these, just over one half (55%) went on to develop multiple sclerosis. These figures are similar to those in the original study (31% and 63% respectively). In 1978 few patients in the ON-only group experienced recurrent attacks (19%). As a result, at this early stage of follow-up, recurrent attacks appeared to be a significant risk factor. Longer follow-up indicates that more patients with isolated optic neuritis will experience a second attack (37% in the present study) if followed for a sufficient length of time. Whether they will later develop lesions outside the optic nerves remains to be determined.
Several conclusions can be drawn from our two surveys on the relationship between optic neuritis, multiple sclerosis and the HLA system. The proportion of patients who develop multiple sclerosis after an attack of optic neuritis increases with length of follow-up; the risk does not decrease significantly with time and the chance that a patient with optic neuritis will escape multiple sclerosis over the suc- 
